SOLAR VASCONCELOS J P 1CHEN N 1TITMUSS E 1池诏丞2
作者信息
- 2. 吉林省肿瘤医院结直肠胃腹部肿瘤外二科 吉林长春 130012
- 折叠
摘要
Abstract
Purpose Sidedness is prognostic and predictive of anti-EGFR efficacy in metastatic colorectal cancer(mCRC).Transverse colon has been historically excluded from several analyses of sidedness and the optimal division between left-and right-sided colorectal cancer is unclear.We investigated transverse colon primary tumor location as a biomarker in mCRC.Experimental design Pooled analysis of CCTG/AGITG CO.17 and CO.20 trials of cetuximab in chemotherapy-refractory mCRC.Outcomes of patients with RAS/BRAF wild-type(WT)mCRC from CO.17 and KRAS WT mCRC from CO.20 were analyzed according to location.Results A total of 553 patients were analyzed,32(5.8%)with cancers from the transverse,101(18.3%)from right,and 420 from(75.9%)left colon.Transverse mCRC failed to reach significant benefit from cetuximab versus best supportive care(BSC)for overall survival[OS;median,5.9 vs.2.1 months;HR,0.63;95%confidence interval(CI),0.28-1.42;P=0.26]and progression-free survival(PFS;median,1.8 vs.1.3 months;HR,0.57;95%CI,0.26-1.28;P=0.16).Analyzing exclusively patients randomized to cetuximab,right-sided and transverse had com-parable outcomes for OS(median,5.6 vs.5.9 months;HR,0.82;95%CI,0.50-1.34;P=0.43)and PFS(median,1.9 vs.1.8 months;HR,0.78;95%CI,0.49-1.26;P=0.31).Patients with left-sided mCRC had superior outcomes with cetuximab compared with transverse for OS(median,9.7 vs.5.9 months;HR,0.42;95%CI,0.27-0.67;P=0.000 2)and PFS(median,3.8 vs.1.8 months;HR,0,49;95%CI,0.31-0.76;P=0.001).Location was not prognostic in patients treated with BSC alone.Conclusions Transverse mCRC has comparable prognostic and predictive features with right-sided mCRC.关键词
横结肠癌/原发肿瘤部位/转移性结直肠癌/预后Key words
transverse colon cancer/primary tumor location/metastatic colorectal cancer/prognosis分类
医药卫生
